Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus PT from Analysts

Aura Biosciences, Inc. (NASDAQ:AURA) has earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $23.00.

A number of equities analysts have recently commented on the company. BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank raised their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. JMP Securities lifted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th.

Insider Transactions at Aura Biosciences

In other news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Los Pinos Elisabet De sold 9,200 shares of the business’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. This represents a 2.79 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,081 shares of company stock worth $891,353. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Long Focus Capital Management LLC lifted its stake in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after acquiring an additional 561,766 shares during the period. Levin Capital Strategies L.P. lifted its position in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares during the period. Franklin Resources Inc. boosted its stake in shares of Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Aura Biosciences during the third quarter worth $1,037,000. Finally, Bank of New York Mellon Corp raised its stake in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Stock Down 1.7 %

AURA opened at $8.08 on Wednesday. The stock has a market capitalization of $403.60 million, a price-to-earnings ratio of -4.67 and a beta of 0.30. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38. The company has a 50-day simple moving average of $9.12 and a 200 day simple moving average of $8.87.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Sell-side analysts anticipate that Aura Biosciences will post -1.66 EPS for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.